Takeda Pharmaceutical Company and Seattle Genetics have reported positive results in a Phase lll clinical trial assessing adcetris (brentuximabvedotin) under a frontline combination chemotherapy regimen for untreated advanced classical Hodgkin’s lymphoma.

The study is a part of the randomised, open-label, two-arm, multi-centre Phase lll ECHELON-1 trial.

ECHELON-1 study met its primary endpoint with the combination of ADCETRIS+AVD, resulting in a statistically significant improvement in modified progression-free survival (PFS) versus the control arm of Adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) as evaluated by an independent review facility (IRF).

The achievement represents a 23% reduction in the risk of progression, death or need for additional anticancer therapy.

Each IRF assessment showed that the two-year modified PFS rate for patients in the ADCETRIS+AVD arm stood at 82.1% compared with 77.2% in the control arm.

“Takeda and Seattle Genetics aim to provide the adcetris-containing regimen to patients with advanced Hodgkin’s lymphoma in the US by the first half of next year.”

In every investigator assessment, the two-year modified PFS rate for patients in the ADCETRIS+AVD arm was 81% compared with 74.4% in the control arm, marking a 27% reduction in the risk of progression, death or need for additional anticancer therapy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

All the secondary endpoints of the Phase lll ECHELON-1 trial also favoured the ADCETRIS+AVD arm, including an interim analysis of overall survival and others.

Takeda vice-president and Oncology Clinical Research and Development head Jesús Gomez Navarro said: “For patients with advanced-stage Hodgkin’s lymphoma, approximately one in three do not achieve long-term remission after standard frontline therapy, which is why the results of ECHELON-1 could be important to this group of patients.”

Takeda and Seattle Genetics aim to provide the adcetris-containing regimen to patients with advanced Hodgkin’s lymphoma in the US by the first half of next year.

Adcetris is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical Hodgkin’s lymphoma and is currently not approved as a frontline therapy for the disease.